A group of tiny RNA that should attack the virus causing COVID-19 when it tries to infect the body are diminished with age and chronic health problems, a decrease that likely helps explain why older individuals and those with preexisting medical conditions are vulnerable populations, investigators report.
MicroRNAs play a big role in our body in controlling gene expression, and also are a front line when viruses invade, latching onto and cutting the RNA, the genetic material of the virus, says Dr. Sadanand Fulzele, aging researcher in the Department of Medicine and Center for Healthy Aging at the Medical College of Georgia at Augusta University.
But with age and some chronic medical conditions, the attacking microRNA numbers dwindle, reducing our ability to respond to viruses, says Dr. Carlos M. Isales, co-director of the MCG Center for Healthy Aging and chief of the MCG Division of Endocrinology, Diabetes and Metabolism.
Much like not having enough troops on the ground in an actual war, the coronavirus is then better able to do what it does naturally, which is hijacking our cell machinery so it can replicate, say the researchers who report in the journal Aging and Disease what appear to be key microRNA involved in responding to this virus. They have a longer-term goal of identifying the biggest hitters and replenishing those troops.
They looked at the RNA sequence of actually two coronaviruses, SARS, which surfaced in 2002, and SARS-CoV-2, which causes COVID-19, and the sequence of the microRNAs that appeared to be attacking the virus, then used computer simulation to figure out which would logically fit together like puzzle pieces. Their perusal included four samples of SARS and 29 samples of SARS-CoV-2, taken between January and April 2020 from five continents covering 17 countries from the United States to Germany to Thailand.
They found 848 microRNAs that target the SARS genome and 873 microRNAs that target SARS-CoV-2 genome. They found 558 of the microRNAs fighting SARS also present in SARS-CoV-2, while 315 microRNAs were unique to SARS-CoV-2, and 290 were unique to SARS. MicroRNAs most proficient at attacking SARS-CoV-2 showed more than 10 target sites and might ultimately be found to be the most proficient at fighting the virus, which, in a few months, has changed much of the way the world functions.
They also found the microRNAs targeting SARS-CoV-2 were associated with more than 72 biological processes — from the production of molecules to the immune response — and that many are known to become dysregulated and/or diminish in number with age and with underlying medical conditions like diabetes and cardiovascular disease, a likely factor in the increased disease presentation and death rates seen in these individuals, the investigators say.
An example is microRNAs like miR-15b-5p, which has a high affinity for SARS-CoV-2, but is downregulated in coronary artery disease, says corresponding author Fulzele. In healthy, younger people, these microRNAs whose nature is to bind to the virus, are more apt to do as they should and prevent replication, he adds.
In the 29 worldwide samples of SARS-CoV-2, 19 had identical microRNAs, which indicates the virus has a fairly uniform presence internationally and that any effective treatments or vaccines should have broad impact, Isales says.
Next steps include studies in culture and lab animals to ensure findings are consistent with the computer analysis of human microRNAs in this study.
“The most important and striking feature of COVID-19 is the increased case fatality rate in aged individuals,” the investigators write, with the CDC reporting that nearly half of patients requiring hospitalization are age 65 and older, and these more senior individuals account for about 80% of the deaths. Fulzele, Isales and their colleagues wanted to know more about why.
“My perspective is there is a key set of microRNAs that are important in triggering this abnormal response, in making older patients more susceptible,” says senior author Isales. “We are looking at microRNAs in general dropping, but there is a specific subset that is key. The question is whether we can we target those as a therapy.”
Cocktails of multiple key microRNA, potentially given through the nose, might help restore sufficient levels of the key virus fighters, the investigators say.
They already are moving toward producing synthetic microRNA that could supplement this frontline weakened by age or disease, Fulzele says. Future studies also include pinning down which microRNA would be most impactful as an adjunct therapy, for example with the drug remdesivir, under study now for COVID-19, which works to stop the virus’ pirating of healthy cell machinery.
Another question to pursue is whether some younger people, who also are seriously sickened by SARS-CoV-2 infection, already don’t make sufficient numbers of some of the key protective microRNA, Isales says.
Image Credit: Envato/Amanda Scott
Thanks to Heinz V. Hoenen. Follow him on twitter: @HeinzVHoenen
News This Week
ANSTO has contributed to a comprehensive investigation of a promising type of nanoparticle that could potentially be used for intractable brain cancers in a combined therapy. The study, which was led by Dr. Moeava [...]
The immune response needed to protect people against reinfection with the coronavirus will be explored in a new human challenge trial, researchers have revealed. Human challenge trials involve deliberately exposing healthy people to a [...]
Researchers from Duke University are developing a flu shot with the new technology that was used for two coronavirus vaccines. Both the Pfizer-BioNTech and the Moderna shots use part of the virus's genetic code [...]
Researchers from the University of Liverpool have shown the potential of repurposing an existing and cheap drug into a long-acting injectable therapy that could be used to treat Covid-19. In a paper published in the journal Nanoscale, [...]
Researchers have developed a new superbug-destroying coating that could be used on wound dressings and implants to prevent and treat potentially deadly bacterial and fungal infections. The material is one of the thinnest antimicrobial [...]
The U.S. is recommending a "pause" in administration of the single-dose Johnson & Johnson COVID-19 vaccine to investigate reports of potentially dangerous blood clots. In a joint statement Tuesday, the Centers for Disease Control [...]
The South African coronavirus variant is better at "breaking through" the defences of the Pfizer/BioNTech vaccine than other forms of the virus, Israeli experts said Sunday. However, one of the authors told AFP that [...]
EPFL scientists have developed AI-powered nanosensors that let researchers track various kinds of biological molecules without disturbing them. The tiny world of biomolecules is rich in fascinating interactions between a plethora of different agents [...]
A team of researchers from the Institute for Infectious Diseases (IFIK) at the University of Bern and the Federal Institute of Virology and Immunology (IVI) have assessed virus growth and activation of the cellular [...]
Researchers at Brown University have succeeded in creating the first wireless, implantable, rechargeable, long-term brain-computer interface. The wireless BCIs have been implanted in pigs and monkeys for over 13 months without issue, and human [...]
The coronavirus outbreak made household names of companies like Moderna Inc. and BioNTech SE, whose shots offered hope for ending the pandemic. Now a new wave of vaccines is on the horizon that may get the [...]
Researchers at the University of Southampton have developed a new way of using nanomaterials to identify and enrich skeletal stem cells—a discovery which could eventually lead to new treatments for major bone fractures and [...]
In March 2020, Hannu Rajaniemi pivoted his biotech company Helix Nanotechnologies' focus from cancer therapies to Covid-19 vaccines. The role biotech start-ups can play in a pandemic Rajaniemi originally co-founded Helix Nanotechnologies in Cambridge, Massachusetts in [...]
The rapid mass testing strategy costing just £1 a day per child can get children back to school and economies up and running, according to experts. That is the small price of the [...]
Covid-19 vaccines are incredibly good at preventing severe symptoms and hospitalization, but they’re probably less effective at stopping transmission. To do that, we might need a different kind of vaccine altogether. Because SARS-CoV-2 is [...]
For many scientists, challenging the idea that SARS-CoV-2 has natural origins is seen as career suicide. But a vocal few say it shouldn't be disregarded or lumped in with conspiracy theories. Nikolai Petrovsky was scrolling [...]